|[January 09, 2014]
Evolva to Launch a Level-1 ADR Programme with BNY Mellon
REINACH, Switzerland --(Business Wire)--
Evolva Holding SA (SIX:EVE) has appointed BNY Mellon, the global
leader in investment management and investment services, to set up a
Level-1 American Depositary Receipt (ADR) programme.
Each Evolva ADR will represent 10 ordinary shares and trade on the OTC
(Over-The-Counter) market in the U.S. Trading in the ADRs is expected to
start in the next few weeks. Evolva's registered common shares continue
to trade on the Swiss Stock Exchange (SIX) under the symbol "EVE" (ISIN:
CH0021218067). Investors can find information on Evolva's ADR on www.bnymellon.com/dr.
The launch of the ADR programme will not result in an increase in the
number of outstanding Evolva shares.
Evolva CFO Jakob Dynnes Hansen commented "This initiative
reflects our growing U.S. footprint. We have operations in the San
Francisco Bay area; key partners such as Cargill and IFF are
headquartered in the U.S.; for many of our products (for example
resveratrol and stevia) the U.S. will be an important market. We are
proud to have a number of well-reputed U.S. investors already holding
our stock and believe these ADRs will make it possibe for more U.S.
investors to participate in the Evolva story."
"We look forward to working with Evolva's management team to build
visibility for its new ADR program among the U.S. investment community,"
said Marianne Erlandsen, managing director and head of EMEA for
BNY Mellon's depositary receipt business.
- ends -
Evolva is a pioneer and global leader in sustainable, fermentation-based
approaches to ingredients for health, wellness and nutrition. Evolva's
products include stevia, vanilla, saffron and resveratrol. As well as
developing its own proprietary ingredients, Evolva also deploys its
technology for partners, providing them with a competitive edge and
sharing in the returns they make. For more information see www.evolva.com.
About American Depositary Receipts
American Depositary Receipts (ADR) are U.S. securities that represent
shares of a non-U.S. company in the U.S. markets. U.S. investors buy
ADRs through their brokers just like any other stock. Brokers have a
choice of buying ADRs and/or buying ordinary shares and converting these
to ADRs with no delay. Level I ADRs trade in the over-the-counter
market. They help to enhance the issuers' visibility in the U.S. and
attract North American investors, reduce shareholder concentration,
increase holdings by high-net-worth individuals and retail ownership,
and increase liquidity of the stock. For more information on ADRs, visit www.bnymellon.com/dr
This press release contains specific forward-looking statements, e.g.
statements including terms like believe, assume, expect or similar
expressions. Such forward-looking statements are subject to known and
unknown risks, uncertainties and other factors which may result in a
substantial divergence between the actual results, financial situation,
development or performance of the company and those explicitly or
implicitly presumed in these statements. Against the background of these
uncertainties readers should not place undue reliance on forward-looking
statements. The company assumes no responsibility to update
forward-looking statements or to adapt them to future events or
[ Back To TMCnet.com's Homepage ]